36 results on '"Tienan Yi"'
Search Results
2. Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma
- Author
-
Hao Liu, Yan Han, Zhantao Liu, Liping Gao, Tienan Yi, Yuandong Yu, Yu Wang, Ping Qu, Longchao Xiang, and Yong Li
- Subjects
OCLR ,Machine learning ,Lung adenocarcinoma ,Neuroendocrine differentiation ,Immunotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Tumours with no evidence of neuroendocrine transformation histologically but harbouring neuroendocrine features are collectively referred to as non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED). Investigating the mechanisms underlying NED is conducive to designing appropriate treatment options for NSCLC patients. Methods In the present study, we integrated multiple lung cancer datasets to identify neuroendocrine features using a one-class logistic regression (OCLR) machine learning algorithm trained on small cell lung cancer (SCLC) cells, a pulmonary neuroendocrine cell type, based on the transcriptome of NSCLC and named the NED index (NEDI). Single-sample gene set enrichment analysis, pathway enrichment analysis, ESTIMATE algorithm analysis, and unsupervised subclass mapping (SubMap) were performed to assess the altered pathways and immune characteristics of lung cancer samples with different NEDI values. Results We developed and validated a novel one-class predictor based on the expression values of 13,279 mRNAs to quantitatively evaluate neuroendocrine features in NSCLC. We observed that a higher NEDI correlated with better prognosis in patients with LUAD. In addition, we observed that a higher NEDI was significantly associated with reduced immune cell infiltration and immune effector molecule expression. Furthermore, we found that etoposide-based chemotherapy might be more effective in the treatment of LUAD with high NEDI values. Moreover, we noted that tumours with low NEDI values had better responses to immunotherapy than those with high NEDI values. Conclusions Our findings improve the understanding of NED and provide a useful strategy for applying NEDI-based risk stratification to guide decision-making in the treatment of LUAD. more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
- Author
-
Jin Li, Shukui Qin, Lu Wen, Junsheng Wang, Wenying Deng, Weijian Guo, Tongfu Jia, Da Jiang, Guifang Zhang, Yifu He, Yi Ba, Haijun Zhong, Lin Wang, Xiaoyan Lin, Jianwei Yang, Jun Zhao, Yuxian Bai, Xiangyuan Wu, Feng Gao, Guogui Sun, Yongjuan Wu, Feng Ye, Qiong Wang, Zhong Xie, Tienan Yi, Yong Huang, Guohua Yu, Lin Lu, Ying Yuan, Wei Li, Likun Liu, Yuping Sun, Ying Sun, Lifeng Yin, and Zhiguo Hou more...
- Subjects
Advanced gastric cancer ,Apatinib ,Third- and later-line treatment ,Phase IV study ,Safety ,Efficacy ,Medicine - Abstract
Abstract Background Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phase IV AHEAD study was conducted to verify the safety and efficacy of apatinib in patients with advanced or metastatic gastric or gastroesophageal adenocarcinoma after at least two lines of systematic therapy in clinical practice settings. Methods Patients with advanced gastric cancer who had previously failed at least two lines of chemotherapy received oral apatinib until disease progression, death or unacceptable toxicity. The primary endpoint was safety. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Adverse events were summarized by the incidence rate. Median OS and PFS were estimated using the Kaplan–Meier method. ORR, DCR, OS at 3 and 6 months, and PFS at 3 and 6 months were calculated, and their 95% CIs were estimated according to the Clopper-Pearson method. Results Between May 2015 and November 2019, a total of 2004 patients were enrolled, and 1999 patients who received at least one dose of apatinib were assessed for safety. In the safety population, 87.9% of patients experienced treatment-related adverse events (TRAEs), with the most common hypertension (45.2%), proteinuria (26.5%), and white blood cell count decreased (25.3%). Additionally, 51% of patients experienced grade ≥ 3 TRAEs. Fatal TRAEs occurred in 57 (2.9%) patients. No new safety concerns were reported. Among the 2004 patients included in the intention-to-treat population, the ORR was 4.4% (95% CI, 3.6–5.4%), and DCR was 35.8% (95% CI, 33.7–38.0%). The median PFS was 2.7 months (95% CI 2.2–2.8), and the median OS was 5.8 months (95% CI 5.4–6.1). Conclusions The findings in the AHEAD study confirmed the acceptable and manageable safety profile and clinical benefit of apatinib in patients with advanced gastric cancer as a third- or later-line of treatment. Trial registration This study was registered with ClinicalTrials.gov NCT02426034. Registration date was April 24, 2015. more...
- Published
- 2023
- Full Text
- View/download PDF
4. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study
- Author
-
Jie Zhang, Yueyin Pan, Qin Shi, Guojun Zhang, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, and Caicun Zhou more...
- Subjects
chemotherapy ,cisplatin ,clinical trial ,gemcitabine ,liposomal paclitaxel (Lipusu) ,locally advanced ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomized, phase 3 study to compare the efficacy and safety of cisplatin plus Lipusu (LP) versus cisplatin plus gemcitabine (GP) as first‐line treatment in locally advanced or metastatic LSCC. Methods Patients enrolled were aged between 18 to 75 years, had locally advanced (clinical stage IIIB, ineligible for concurrent chemoradiation or surgery) or metastatic (Stage IV) LSCC, had no previous systemic chemotherapy and at least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (version 1.1) before administration of the trial drug. The primary endpoint was progression‐free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. To explore the possible predictive value of plasma cytokines for LP treatment, plasma samples were collected from the LP group at baseline and first efficacy evaluation time and were then subjected to analysis by 45‐Plex ProcartaPlex Panel 1 to detect the presence of 45 cytokines using the Luminex xMAP technology. The correlation between treatment outcomes and dynamic changes in the levels of cytokines were evaluated in preliminary analyses. Results The median duration of follow‐up was 15.4 months. 237 patients in the LP group and 253 patients in the GP group were included in the per protocol set (PPS). In the PPS, the median PFS was 5.2 months versus 5.5 months in the LP and GP group (hazard ratio [HR]: 1.03, P = 0.742) respectively. The median OS was 14.6 months versus 12.5 months in the LP and GP group (HR: 0.83, P = 0.215). The ORR (41.8% versus 45.9%, P = 0.412) and DCR (90.3% versus 88.1%, P = 0.443) were also similar between the LP and GP group. A significantly lower proportion of patients in the LP group experienced adverse events (AEs) leading to treatment interruptions (10.9% versus 26.4%, P < 0.001) or treatment termination (14.3% versus 23.1%, P = 0.011). The analysis of cytokine levels in the LP group showed that low baseline levels of 27 cytokines were associated with an increased ORR, and 15 cytokines were associated with improved PFS, with 14 cytokines, including TNF‐α, IFN‐γ, IL‐6, and IL‐8, demonstrating an overlapping trend. Conclusion The LP regimen demonstrated similar PFS, OS, ORR and DCR as the GP regimen for patients with locally advanced or metastatic LSCC but had more favorable toxicity profiles. The study also identified a spectrum of different cytokines that could be potentially associated with the clinical benefit in patients who received the LP regimen. more...
- Published
- 2022
- Full Text
- View/download PDF
5. The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study
- Author
-
Weineng Feng, Yufeng Wang, Fengming Ran, Yong Mao, Helong Zhang, Qifeng Wang, Wen Lin, Zhidong Wang, Jianli Hu, Wangjun Liao, Tao Zhang, Qian Chu, Weijie Xiong, Tienan Yi, Jiqun Yi, Shoucheng Ma, Yi Sun, Lingzhan Meng, Chunling Liu, Silang Zhou, Dengyun Zheng, Shubin Wang, Haifeng Lin, Wenzheng Fang, Jun Li, and Minhui Wu more...
- Subjects
immediate-release (IR) morphine ,controlled-release (CR) oxycodone ,cancer pain ,dose titration ,oxycodone hydrochloride ,pain remission ,Medicine (General) ,R5-920 - Abstract
BackgroundOxycodone hydrochloride is a semisynthetic narcotic analgesic agent. This study aimed to explore optimal titration strategy of controlled-release (CR) oxycodone hydrochloride in patients with cancer pain.Methods258 patients, who used regular strong opioids (morphine and CR oxycodone hydrochloride) for cancer pain across 25 three grade class hospitals in China during January 15th 2017 to April 30th 2017, were retrospectively studied. The patients were divided into 4 groups according to treatment regimens titrated. The pain remission rate and numeric rating scale (NRS) of cancer pain was recorded at 0, 12, 24, 36, 48, 60, 72 h after opioid titration. The incidence of adverse events (AEs) with therapy were also observed.Results12 h after treatment, pain remission rate of Group B, C and D was significantly higher (P < 0.001) than Group A. For the complete remission rate, there were also significant differences among the four groups (P < 0.001). No significant difference was found among four groups for pain remission rate at 24, 72 h after treatment. Multiple comparison of NRS scores showed that the both Group B and C varied significantly with Group D (P = 0.028, P = 0.05, respectively), showing superior analgesic effect over Group D. AEs were significantly different among groups (P < 0.01), with the most frequent AEs in Group A, lowest in Group B.ConclusionThe rapid titration strategy of background CR oxycodone hydrochloride was effectiveness and safety in patients with moderate-to-severe cancer pain. more...
- Published
- 2022
- Full Text
- View/download PDF
6. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study
- Author
-
Xiaorong Dong, Yu Huang, Tienan Yi, Chunhong Hu, Quanli Gao, Yuan Chen, Jing Zhang, Jianhua Chen, Li Liu, Rui Meng, Sheng Zhang, Xiaofang Dai, Shihong Fei, Yang Jin, Ping Yin, Yanping Hu, and Gang Wu
- Subjects
intrapleural infusion ,methotrexate ,microparticles ,malignant pleural effusion ,non-squamous non-small cell lung cancer ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundPreclincal studies showed the promising efficacy of tumor cell-derived microparticles packaging methotrexate (TMPs-MTX) to treat advanced non-squamous non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE).MethodsThis randomized, double-blind, placebo-controlled study was conducted at six hospitals in China from 20 July 2015 to 25 April 2019. Patients newly diagnosed with non-squamous NSCLC with MPE were randomly assigned to receive TMPs-MTX (group A) or saline (group B). Patients in both groups received pemetrexed (500 mg/m2 d1) and cisplatin (75 mg/m2 in total for d1-d2). Intrapleural infusion (50 mL saline containing 5 units of TMPs-MTX per perfusion, once every 48 hours, six total perfusions) was initiated on day 5 after pemetrexed-cisplatin chemotherapy. The primary outcome was the objective response rate (ORR) of MPE. Secondary outcomes included the ORR of target lesions, progression-free survival (PFS), overall survival (OS), toxicity, and pleural fluid properties.ResultsA total of 86 patients were enrolled in this study and randomly assigned to either group A or group B. Of these, 79 patients were evaluable for response. The ORR of MPE in group A was significantly higher than that in group B (82.50% vs. 58.97%, P = 0.0237). The ORR of target lesions was 25.64% in group A and 20.51% in group B (P = 0.5909), respectively. With a median follow-up time of 18.8 months, median PFS were 6.4 (95% CI, 4.5-12.3) months in group A and 7.3 (95% CI, 6.1-10.4) months in group B (P = 0.6893), and median OS were 19.9 (95% CI, 17.1-28.5) months and 17.5 (95% CI, 11.6-25.0) months (P = 0.4500), respectively. The incidence rates of adverse events were similar in the two groups. The most common treatment-related adverse events were chemotherapy-induced toxicities, including fever, gastrointestinal reactions, hepatic dysfunction, and leukopenia.ConclusionIntrapleural infusion of TMPs-MTX combined with pemetrexed-cisplatin chemotherapy is safe and effective against MPE in patients with advanced non-squamous NSCLC.Clinical trial registrationhttp://www.chictr.org.cn (ChiCTR-ICR-15006304). more...
- Published
- 2022
- Full Text
- View/download PDF
7. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
- Author
-
Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, and Can Wu more...
- Subjects
anti‐angiogenesis ,anti‐VEGF monoclonal antibody ,avastin ,bevacizumab ,biosimilar ,non‐small cell lung cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first‐line treatment of Chinese patients with advanced or recurrent non‐squamous non‐small cell lung cancer (NSCLC). Methods Stage IIIB‐IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4‐6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression‐free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results Between December 15th, 2017, and May 15th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1‐6) and median duration of treatment of 3.0 (range 0.0‐5.1) months. ORR of response‐evaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%, respectively. The stratified ORR ratio was 0.91 (90% CI 0.80‐1.04, within the prespecified equivalence margin of 0.75‐1.33). Up to May 15th, 2020, with a median follow‐up of 13.6 (range 0.8‐28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1‐year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non‐squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non‐squamous NSCLC patients in the first‐line setting. more...
- Published
- 2021
- Full Text
- View/download PDF
8. Retracted: Long non‐coding RNA TP73‐AS1 facilitates progression and radioresistance in lung cancer cells by the miR‐216a‐5p/CUL4B axis with exosome involvement
- Author
-
Huibing Qiu, Lingyun Zhang, Tienan Yi, Kai Yang, Yan Gong, and Conghua Xie
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Retraction: Qiu, H., Zhang, L., Yi, T., Yang, K., Gong, Y. and Xie, C. (2020), Long non‐coding RNA TP73‐AS1 facilitates progression and radioresistance in lung cancer cells by the miR‐216a‐5p/CUL4B axis with exosome involvement. Thorac Cancer. https://doi.org/10.1111/1759-7714.13602The above article, published online on 25 August 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement among the authors, the journal Editor in Chief Qinghua Zhou, and John Wiley & Sons Ltd. The retraction has been agreed after the results reported in Figures 3B, 3C, 3I, and 3J were found to be not repeatable in authors' further study. more...
- Published
- 2021
- Full Text
- View/download PDF
9. A Randomized Trial of NVB plus DDP with Versus without Thalidomide in the Treatment of Advanced Non Small Cell Lung Cancer
- Author
-
Xiaoling ZHANG, Bin LUO, Tienan YI, and Qiushan HE
- Subjects
Lung neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2008
10. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
- Author
-
Yuankai, Shi, Shiman, Wu, Ke, Wang, Shundong, Cang, Wenxiu, Yao, Yun, Fan, Lin, Wu, Meijuan, Huang, Xingya, Li, Yueyin, Pan, Zhixiong, Yang, Bo, Zhu, Gongyan, Chen, Jianhua, Shi, Meili, Sun, Jian, Fang, Lijun, Wang, Zhaohong, Chen, Chunling, Liu, Jingzhang, Li, Jiwei, Liu, Shenghua, Sun, Yanqiu, Zhao, Yanzhen, Guo, Zili, Meng, Zhefeng, Liu, Zhigang, Han, Hong, Lu, Rui, Ma, Sheng, Hu, Guofang, Zhao, Zheng, Liu, Congying, Xie, Diansheng, Zhong, Hui, Zhao, Huiqing, Yu, Longzhen, Zhang, Minghong, Bi, Shanyong, Yi, Shuliang, Guo, Tienan, Yi, Wen, Li, Yingcheng, Lin, Yongqian, Shu, Zhendong, Chen, Zhongliang, Guo, Michael, Greco, Tingting, Wang, and Haijiao, Shen more...
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Abstract
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFR T790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC.Patients with locally advanced or metastatic/recurrent NSCLC with confirmed EGFR T790M mutation who progressed after first-/second-generation EGFR TKI therapy or primary EGFR T790M mutation were enrolled. Patients received rezivertinib at 180 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary end point was objective response rate (ORR) assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included disease control rate (DCR), duration of response, progression-free survival (PFS), overall survival, and safety. This study is registered with Clinical Trials.gov (NCT03812809).A total of 226 patients were enrolled from July 5, 2019, to January 22, 2020. By the data cutoff date on January 24, 2022, the median duration of follow-up was 23.3 months (95% confidence interval [CI]: 22.8-24.0). The ORR by blinded independent central review was 64.6% (95% CI: 58.0%-70.8%), and DCR was 89.8% (95% CI: 85.1%-93.4%). The median duration of response was 12.5 months (95% CI: 10.0-13.9), and median PFS was 12.2 months (95% CI: 9.6-13.9). The median overall survival was 23.9 months (95% CI: 20.0-not calculated [NC]). Among 91 (40.3%) patients with central nervous system (CNS) metastases, the median CNS PFS was 16.6 months (95% CI: 11.1-NC). In 29 patients with more than or equal to one brain target lesion at baseline, the CNS ORR and CNS DCR were 69.0% (95% CI: 49.2%-84.7%) and 100% (95% CI: 88.1%-100%), respectively. Time to progression of CNS was 16.5 months (95% CI: 9.7-NC). Of 226 patients, 188 (83.2%) had at least one treatment-related adverse event, whereas grade more than or equal to 3 occurred in 45 (19.9%) patients. No interstitial lung disease was reported.Rezivertinib was found to have promising efficacy and favorable safety profile for patients with locally advanced or metastatic/recurrent NSCLC with EGFR T790M mutation. more...
- Published
- 2022
- Full Text
- View/download PDF
11. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study
- Author
-
Ziping Wang, Tienan Yi, Yun Fan, Guangqiang Zhao, Guangfa Wang, Gongyan Chen, Yong Song, Aimin Zang, Wenxiu Yao, Kangsheng Gu, Junfeng Liu, Caicun Zhou, Guohua Yu, Jianxing He, Jianling Bai, Huijuan Wang, Da Jiang, Xiaochun Zhang, Xiaohua Hu, Jie Zhang, Liyan Jiang, Kai Chen, Jiuwei Cui, Wenmin Xie, Qisen Guo, Lihong Wu, Chunhong Hu, Xiaorong Dong, Yueyin Pan, Junling Li, Guojun Zhang, Nong Yang, Min Peng, Xiaohong Wu, Lu Yue, Jianping Xiong, Qin Shi, Weihong Zhao, Yuping Li, and Wei Tan more...
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,Paclitaxel ,medicine.medical_treatment ,Phases of clinical research ,cisplatin ,multicenter ,chemotherapy ,Deoxycytidine ,Young Adult ,liposomal paclitaxel (Lipusu) ,plasma cytokines ,Internal medicine ,locally advanced ,Antineoplastic Combined Chemotherapy Protocols ,lung squamous cell carcinoma ,Clinical endpoint ,medicine ,Humans ,Lung ,RC254-282 ,Aged ,Cisplatin ,Chemotherapy ,business.industry ,Hazard ratio ,gemcitabine ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,clinical trial ,Original Articles ,Middle Aged ,Gemcitabine ,metastatic ,Regimen ,Response Evaluation Criteria in Solid Tumors ,Liposomes ,Carcinoma, Squamous Cell ,Original Article ,business ,medicine.drug - Abstract
Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomized, phase 3 study to compare the efficacy and safety of cisplatin plus Lipusu (LP) versus cisplatin plus gemcitabine (GP) as first‐line treatment in locally advanced or metastatic LSCC. Methods Patients enrolled were aged between 18 to 75 years, had locally advanced (clinical stage IIIB, ineligible for concurrent chemoradiation or surgery) or metastatic (Stage IV) LSCC, had no previous systemic chemotherapy and at least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (version 1.1) before administration of the trial drug. The primary endpoint was progression‐free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. To explore the possible predictive value of plasma cytokines for LP treatment, plasma samples were collected from the LP group at baseline and first efficacy evaluation time and were then subjected to analysis by 45‐Plex ProcartaPlex Panel 1 to detect the presence of 45 cytokines using the Luminex xMAP technology. The correlation between treatment outcomes and dynamic changes in the levels of cytokines were evaluated in preliminary analyses. Results The median duration of follow‐up was 15.4 months. 237 patients in the LP group and 253 patients in the GP group were included in the per protocol set (PPS). In the PPS, the median PFS was 5.2 months versus 5.5 months in the LP and GP group (hazard ratio [HR]: 1.03, P = 0.742) respectively. The median OS was 14.6 months versus 12.5 months in the LP and GP group (HR: 0.83, P = 0.215). The ORR (41.8% versus 45.9%, P = 0.412) and DCR (90.3% versus 88.1%, P = 0.443) were also similar between the LP and GP group. A significantly lower proportion of patients in the LP group experienced adverse events (AEs) leading to treatment interruptions (10.9% versus 26.4%, P < 0.001) or treatment termination (14.3% versus 23.1%, P = 0.011). The analysis of cytokine levels in the LP group showed that low baseline levels of 27 cytokines were associated with an increased ORR, and 15 cytokines were associated with improved PFS, with 14 cytokines, including TNF‐α, IFN‐γ, IL‐6, and IL‐8, demonstrating an overlapping trend. Conclusion The LP regimen demonstrated similar PFS, OS, ORR and DCR as the GP regimen for patients with locally advanced or metastatic LSCC but had more favorable toxicity profiles. The study also identified a spectrum of different cytokines that could be potentially associated with the clinical benefit in patients who received the LP regimen., Cisplatin plus Lipusu (LP) regimen has comparable efficacy and more favorable toxicity profiles compared with cisplatin plus gemcitabine (GP) regimen for patients with advanced LSCC. The study also demonstrated that LP had a significant impact on the levels of plasma cytokines and a spectrum of cytokines were associated with clinical benefit in patients who received LP. Thus, our results provided a new option for patients with advanced LSCC. more...
- Published
- 2022
12. Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials
- Author
-
Yuankai Shi, Sheng Yang, Shiman Wu, Yanqiu Zhao, Gongyan Chen, Bo Zhu, Xingya Li, Ke Wang, Jianhua Shi, Shundong Cang, Wenxiu Yao, Yun Fan, Jian Fang, Liangming Zhang, Jianying Zhou, Lin Wu, Rongsheng Zheng, Meijuan Huang, Yueyin Pan, Zhixiong Yang, Meili Sun, Huiqing Yu, Donglin Wang, Jian-an Huang, Lijun Wang, Yongqian Shu, Zhaohong Chen, Chunling Liu, Jingzhang Li, Jiwei Liu, Shenghua Sun, Yanzhen Guo, Zili Meng, Zhefeng Liu, Zhigang Han, Gang Wu, Hong Lu, Rui Ma, Shen Hu, Guofang Zhao, Longzhen Zhang, Zheng Liu, Congying Xie, Diansheng Zhong, Hui Zhao, Minghong Bi, Shanyong Yi, Shuliang Guo, Tienan Yi, Wen Li, Yingcheng Lin, Zhendong Chen, Zhixiang Zhuang, Zhongliang Guo, Michael Greco, Tingting Wang, and Anqi Zhou more...
- Published
- 2023
- Full Text
- View/download PDF
13. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
- Author
-
Zhongliang Guo, Jian Fang, Junhong Zhang, Puyuan Xing, Xiaoli Zhu, Changlu Hu, Yuming Jia, Ming Zhou, Zhiwei Lu, Bin Wang, Ke Wang, Yiping Zhang, Lin Wu, Zhanyu Pan, Yanju Chen, Junquan Yang, Shuhua Han, Yongqian Shu, Lianke Liu, Bingqiang Ni, Yong Liu, Hongming Pan, Rongyu Liu, Shengming Liu, Qian Sun, Feng Ye, Qinhong Zheng, Guojun Zhang, Tiegang Tang, Tianjiang Ma, Jianyong Zhang, Bo Jiang, Mafei Kang, Zhiguo Luo, Wenjuan Lian, Can Wu, Lijun Ma, Zhiyong He, Wensheng Qiu, Dongqing Lv, Zheng Liu, Qisen Guo, Dedong Wu, Ke Xiao, Xia Yuan, Jun Chen, Yan Yu, Yuankai Shi, Guolei Wang, Dongji Chen, Shuyang Zhu, Jianhua Shi, Guolong Liu, Hua Zhang, Hongbing Duan, Bo Qiu, Wangjun Liao, Shumin Wang, Jinsheng Shi, Tienan Yi, Hong Lu, Xueli Yuan, Emei Gao, Yimin Mao, Xicheng Wang, Li Zhao, Xiaohong Wu, Yanqiu Zhao, Yan Wang, Kaijian Lei, Yinghua Ji, Yulong Zheng, Minghong Bi, Manxiang Li, Debin Sun, and Yuan Chen more...
- Subjects
0301 basic medicine ,Oncology ,non‐small cell lung cancer ,Cancer Research ,medicine.medical_specialty ,China ,anti‐angiogenesis ,Lung Neoplasms ,Bevacizumab ,LY01008 ,bevacizumab ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,Stage (cooking) ,Biosimilar Pharmaceuticals ,avastin ,RC254-282 ,vascular endothelial growth factor ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Original Articles ,Carboplatin ,030104 developmental biology ,Treatment Outcome ,chemistry ,Paclitaxel ,Response Evaluation Criteria in Solid Tumors ,030220 oncology & carcinogenesis ,Toxicity ,anti‐VEGF monoclonal antibody ,Original Article ,biosimilar ,business ,medicine.drug - Abstract
Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first‐line treatment of Chinese patients with advanced or recurrent non‐squamous non‐small cell lung cancer (NSCLC). Methods Stage IIIB‐IV NSCLC patients with evaluable lesions, good physical status, and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin (combined treatment) for 4‐6 cycles, followed by maintenance monotherapy with LY01008 until disease progression, intolerable toxicity, or death. The primary endpoint was objective response rate (ORR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by independent radiological review committees (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression‐free survival (PFS), overall survival (OS), and safety. This study was registered in ClinicalTrials.gov (NCT03533127). Results Between December 15th, 2017, and May 15th, 2019, a total of 649 patients were randomized to the LY01008 (n = 324) or Avastin (n = 325) group. As of September 25th, 2019 for primary endpoint analysis, 589 patients received ORR evaluation, with a median number of combined treatment cycles of 5 (range 1‐6) and median duration of treatment of 3.0 (range 0.0‐5.1) months. ORR of response‐evaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%, respectively. The stratified ORR ratio was 0.91 (90% CI 0.80‐1.04, within the prespecified equivalence margin of 0.75‐1.33). Up to May 15th, 2020, with a median follow‐up of 13.6 (range 0.8‐28.4) months, no notable differences in DCR, median DoR, median PFS, median OS, and 1‐year OS rate were observed between the LY01008 and Avastin groups. There were no clinically meaningful differences in safety and immunogenicity across treatment groups. Conclusions LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non‐squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non‐squamous NSCLC patients in the first‐line setting., This study demonstrated similarity between LY01008 and reference bevacizumab (Avastin) in terms of efficacy, safety, and immunogenicity in combination with paclitaxel and carboplatin as first‐line treatment in Chinese patients with advanced non‐squamous NSCLC. more...
- Published
- 2021
14. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies
- Author
-
Sheng Yang, Shiman Wu, Yanqiu Zhao, Gongyan Chen, Bo Zhu, Xingya Li, Ke Wang, Jianhua Shi, Shundong Cang, Wenxiu Yao, Yun Fan, Jian Fang, Liangming Zhang, Jianying Zhou, Lin Wu, Rongsheng Zheng, Meijuan Huang, Yueyin Pan, Zhixiong Yang, Meili Sun, Huiqing Yu, Donglin Wang, Jianan Huang, Lijun Wang, Yongqian Shu, Zhaohong Chen, Chunling Liu, Jingzhang Li, Jiwei Liu, Shenghua Sun, Yanzhen Guo, Zili Meng, Zhefeng Liu, Zhigang Han, Gang Wu, Hong Lu, Rui Ma, Sheng Hu, Guofang Zhao, Longzhen Zhang, Zheng Liu, Congying Xie, Diansheng Zhong, Hui Zhao, Minghong Bi, Shanyong Yi, Shuliang Guo, Tienan Yi, Wen Li, Yingcheng Lin, Zhendong Chen, Zhixiang Zhuang, Zhongliang Guo, Michael Greco, Tingting Wang, Anqi Zhou, and Yuankai Shi more...
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
15. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma
- Author
-
Nong Yang, Liyan Jiang, Ziping Wang, Huijuan Wang, Jianxing He, Aimin Zang, Caicun Zhou, Chunhong Hu, Yun Fan, Wenxiu Yao, Junfeng Liu, Wenmin Xie, Qisen Guo, Tao Jiang, Guohua Yu, Jianping Xiong, Min Peng, Kangsheng Gu, Yueyin Pan, Xiaorong Dong, Yuping Li, Qin Shi, Da Jiang, Junling Li, Weihong Zhao, Guojun Zhang, Shengxiang Ren, Xiaochun Zhang, Guangfa Wang, Wei Tan, Guangqiang Zhao, Xiaohong Wu, Tienan Yi, Yi Zhao, Henghui Zhang, Yong Song, Kai Chen, Jiuwei Cui, Gongyan Chen, Lu Yue, Lihong Wu, Dandan Liang, Xiaohua Hu, and Lu Fang more...
- Subjects
Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Treatment response ,Lung Neoplasms ,DNA Copy Number Variations ,Paclitaxel ,medicine.medical_treatment ,Medicine (miscellaneous) ,chemotherapy ,Deoxycytidine ,Circulating Tumor DNA ,cell-free DNA ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Aged ,Chemotherapy ,business.industry ,Lung squamous cell carcinoma ,Middle Aged ,Prognosis ,Gemcitabine ,Progression-Free Survival ,Circulating Cell-Free DNA ,Treatment efficacy ,Survival Rate ,Treatment Outcome ,030104 developmental biology ,machine learning ,Cell-free fetal DNA ,030220 oncology & carcinogenesis ,Cohort ,Carcinoma, Squamous Cell ,Female ,Cisplatin ,First line chemotherapy ,business ,Cell-Free Nucleic Acids ,Non-small-cell lung cancer ,Research Paper - Abstract
Rationale: Platinum-based chemotherapy is one of treatment mainstay for patients with advanced lung squamous cell carcinoma (LUSC) but it is still a "one-size fits all" approach. Here, we aimed to investigate the predictive and monitoring role of circulating cell-free DNA (cfDNA) profiling for the outcome of first-line chemotherapy in patients with advanced LUSC. Methods: Peripheral blood samples of 155 patients from a phase IV trial and 42 cases from an external real-world cohort were prospectively collected. We generated a copy number variations-based classifier via machine learning algorithm to integrate molecular profiling of cfDNA, named RESPONSE SCORE (RS) to predict the treatment outcome. To monitor the treatment efficacy, cfDNA samples collected at different time points were subjected to an ultra-deep sequencing platform. Results: The results showed that patients with high RS showed substantially higher objective response rate than those with low RS in training set (P < 0.001), validation set (P < 0.001) and real-world cohort (P = 0.019). Furthermore, a significant difference was observed in both progression-free survival (training set, P < 0.001; validation set: P < 0.001; real-world cohort: P = 0.019) and overall survival (training set, P < 0.001; validation set: P = 0.037) between high and low RS group. Notably, variant allele frequency (VAF) calculated from an ultra-deep sequencing platform significantly reduced in patients experienced a complete or partial response after 2 cycles of chemotherapy (P < 0.001), while it significantly increased in these of non-responder (P < 0.001). Moreover, VAF undetectable after 2 cycles of chemotherapy was correlated with markedly better objective response rate (P < 0.001) and progression-free survival (P < 0.001) than those with detectable VAF. Conclusions: These findings indicated that the RS, a circulating cfDNA sequencing-based stratification index, could help to guide first-line chemotherapy in advanced LUSC. The change of VAF is valuable to monitor the treatment response. more...
- Published
- 2021
16. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
- Author
-
Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Hong Jian, Chengshui Chen, Xiangming Jin, Panwen Tian, Kai Wang, Guanming Jiang, Gongyan Chen, Qun Chen, Hui Zhao, Cuimin Ding, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Zhe Liu, Jian Fang, Junquan Yang, Wu Zhuang, Yunpeng Liu, Jian Zhang, Yueyin Pan, Jun Chen, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang, Lieming Ding, Ling Zhang, Xiaobin Yuan, Lin Yao, and Zhilin Shen more...
- Subjects
Pulmonary and Respiratory Medicine ,ErbB Receptors ,Acrylamides ,Aniline Compounds ,Lung Neoplasms ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Mutation ,Humans ,Protein Kinase Inhibitors - Abstract
Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy.This was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression after prior first- or second-generation EGFR TKI therapy received oral befotertinib of 50 mg (cohort A) or 75 to 100 mg (cohort B) once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156.A total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75-100 mg), respectively. At data cutoff (August 15, 2021), independent review committee-assessed ORR was 67.6% (95% confidence interval [CI]: 61.9%-72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%-61.5%) in cohort A and 65.9% (95% CI: 60.1%-71.3%) in cohort B. The median investigator-assessed progression-free survival was 11.0 (95% CI: 9.6-12.5) months in cohort A and 12.5 (95% CI: 11.1-13.8) months in cohort B. The median independent review committee-assessed progression-free survival in cohort B was 16.6 (95% CI: 15.0-not evaluable [NE]) months. The intracranial ORR was 26.7% (95% CI: 7.8%-55.1%) in cohort A by investigator assessment, while 57.1% (95% CI: 34.0%-78.2%) and 55.9% (95% CI: 37.9%-72.8%) in cohort B by investigator and independent review committee assessment, respectively. The median investigator-assessed intracranial progression-free survival was 16.5 (95% CI: 8.6-NE) months in cohort A, while the median intracranial progression-free survival was not evaluable in cohort B due to immature data regardless of investigator or independent review committee assessment. and NE (95% CI: 13.8-NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A and in 29.3% and 10.0% of patients in cohort B, respectively.Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first- or second-generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072). more...
- Published
- 2022
17. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
- Author
-
Lin, Shen, Ken, Kato, Sung-Bae, Kim, Jaffer A, Ajani, Kuaile, Zhao, Zhiyong, He, Xinmin, Yu, Yongqian, Shu, Qi, Luo, Jufeng, Wang, Zhendong, Chen, Zuoxing, Niu, Longzhen, Zhang, Tienan, Yi, Jong-Mu, Sun, Jianhua, Chen, Guohua, Yu, Chen-Yuan, Lin, Hiroki, Hara, Qing, Bi, Taroh, Satoh, Roberto, Pazo-Cid, Hendrick-Tobias, Arkenau, Christophe, Borg, Florian, Lordick, Liyun, Li, Ningning, Ding, Aiyang, Tao, Jingwen, Shi, and Eric, Van Cutsem more...
- Subjects
Cancer Research ,Science & Technology ,Oncology ,Esophageal Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Docetaxel ,Esophageal Squamous Cell Carcinoma ,OPEN-LABEL ,Antibodies, Monoclonal, Humanized ,Life Sciences & Biomedicine - Abstract
PURPOSE Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after first-line systemic therapy. PATIENTS AND METHODS In this open-label phase III clinical study, patients with advanced or metastatic ESCC, whose tumor progressed after first-line systemic treatment, were randomly assigned (1:1) to receive intravenous tislelizumab, an anti–programmed cell death protein 1 antibody, 200 mg every 3 weeks or chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan). The primary end point was overall survival (OS) in all patients. The key secondary end point was OS in patients with programmed death-ligand 1 tumor area positivity (TAP) score ≥ 10%. RESULTS In total, 512 patients across 11 countries/regions were randomly assigned. At final analysis, conducted after 410 death events occurred, OS was significantly longer with tislelizumab versus chemotherapy in all patients (median, 8.6 v 6.3 months; hazard ratio [HR], 0.70 [95% CI, 0.57 to 0.85]; one-sided P = .0001), and in patients with TAP ≥ 10% (median, 10.3 months v 6.8 months; HR, 0.54 [95% CI, 0.36 to 0.79]; one-sided P = .0006). Survival benefit was consistently observed across all predefined subgroups, including those defined by baseline TAP score, region, and race. Treatment with tislelizumab was associated with higher objective response rate (20.3% v 9.8%) and a more durable antitumor response (median, 7.1 months v 4.0 months) versus chemotherapy in all patients. Fewer patients experienced ≥ grade 3 treatment-related adverse events (18.8% v 55.8%) with tislelizumab versus chemotherapy. CONCLUSION Tislelizumab significantly improved OS compared with chemotherapy as second-line therapy in patients with advanced or metastatic ESCC, with a tolerable safety profile. Patients with programmed death-ligand 1 TAP ≥ 10% also demonstrated statistically significant survival benefit with tislelizumab versus chemotherapy. more...
- Published
- 2022
18. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb Study
- Author
-
Yuankai Shi, Shiman Wu, Ke Wang, Shundong Cang, Wenxiu Yao, Yun Fan, Lin Wu, Meijuan Huang, Xingya Li, Yueyin Pan, Zhixiong Yang, Bo Zhu, Gongyan Chen, Jianhua Shi, Meili Sun, Jian Fang, Lijun Wang, Zhaohong Chen, Chunling Liu, Jingzhang Li, Jiwei Liu, Shenghua Sun, Yanqiu Zhao, Yanzhen Guo, Zili Meng, Zhefeng Liu, Zhigang Han, Hong Lu, Rui Ma, Shen Hu, Guofang Zhao, Zheng Liu, Congying Xie, Diansheng Zhong, Hui Zhao, Huiqing Yu, Longzhen Zhang, Minghong Bi, Shanyong Yi, Shuliang Guo, Tienan Yi, Wen Li, Yingcheng Lin, Yongqian Shu, Zhendong Chen, Zhongliang Guo, Michael Greco, Tingting Wang, and Haijiao Shen more...
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
- Full Text
- View/download PDF
19. A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer
- Author
-
Jinlin Wang, Tienan Yi, Youhong Dong, Xinhua Xu, Fengjun Cao, Ruizhi Ran, Yifa Yin, Yinping Li, Yang Fu, Yanhua Xu, Li Kuang, Guiming Chen, Guangqiao Qu, Jun Li, Zhiguo Luo, Yuan Chen, Qibin Song, and Qian Chu more...
- Subjects
Cancer Research ,Oncology - Abstract
e21106 Background: Anlotinib is an oral novel receptor tyrosine kinases (RTKs) inhibitor targeting multiple RTKs including VEGFR, PDGFR, FGFR, and c-kit. Due to its high efficacy and low side effects in ALTER 0303 trial, Anlotinib has been approved as a 3rd line therapy for pts with advanced non-small cell lung cancer (NSCLC) by NMPA in May 2018. The interim results of our real-world study suggested anlotinib substantially prolonged the progression-free survival (PFS) with manageable toxicity in later lines treatment of advanced NSCLC patients. Here, we update our latest results on the treatment experience in a broad NSCLC population. Methods: This is a multi-center, non-interventional, prospective real-world study. All registered data are collected from real-life clinical practice setting. Patients with advanced NSCLC treating with anlotinib were included. The primary endpoint was PFS, and the secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. Results: As of January 2022, a total of 371 pts were enrolled, of whom 347 were evaluable, with a median age of 63 years, 232 males (66.9%). There were 40 pts (11.5%) with brain metastasis, 52 pts (15.0%) with bone metastasis, and 29 pts (8.4%) with liver metastasis at baseline. 109 pts (31.4%) received anlotinib as first/second line treatment, whereas 238 pts (68.6%) as third/later line treatment. In the overall population, DCR and ORR were 84.7% and 18.7% respectively. The mPFS was 6.3 months (95%CI, 5.7, 6.9) and the mOS was 12.2 months (95%CI, 9.5,14.9). Subgroup analysis showed more details. A trend towards better ORR (33.3%) was observed in the first line setting while a significantly better DCR (89.5%) was observed in the second line setting. The mPFS of first-/second-line treatment (6.9 months) was longer than that of the third-line or above treatment (5.8 months). The mOS of the first-/second- and third-line or above treatment were 10.4 (7.8,13) and 13.5 (8.9,18.1) months respectively. 52 pts (15%) had any grade of adverse events, of which 10 pts (2.9%) had grade 3 or above AEs. The most common AEs were hypoalbuminemia (3.5%), alanine aminotransferase reduction (1.4%), proteinuria (1.2%) and hyponatremia (1.2%). Conclusions: The updated results showed that anlotinib prolonged not only PFS but also OS significantly with a favorable safety profile, especially for OS benefits in third-line or later treatment. These data also indirectly revealed that anlotinib is a promising treatment option for patients with advanced NSCLC despite of treatment line in the real world. more...
- Published
- 2022
- Full Text
- View/download PDF
20. Systematic investigations of COVID-19 in 283 cancer patients
- Author
-
Youhong Dong, Xiuli Luo, Jie Wang, Ruizhi Ran, Jie He, Gang Feng, Dongfeng Pan, Xiaorong Dong, Jie Ren, Mingyu Liu, Zuowei Hu, Tienan Yi, Xinhua Xu, Liqiong Luo, Jianhai Sun, Yanhua Xu, Liu Jing, Zhijie Wang, Yang Yang, Yuan Chen, Qian Chu, Li Kuang, Yu Xu, Jiyuan Yang, Qun Wang, H. Lu, Guoqiang Wang, Jun Jin, Shangli Cai, Qibin Song, Hanlin Wu, Linjun Li, Zhihong Zhang, Zhengyi Zhao, Wenbing Hu, Zhiguo Rao, Jiachen Xu, Zhibin Xie, Bin Xu, Weidong Hu, Runkun Wang, Hongyun Gong, Chiding Hu, Zhiguo Luo, and Jianchun Duan more...
- Subjects
Survival Status ,medicine.medical_specialty ,Chemotherapy ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Mortality rate ,medicine.medical_treatment ,Clinical course ,Cancer ,medicine.disease ,Internal medicine ,Cohort ,medicine ,In patient ,business - Abstract
sBackgroundCancer patients are considered to be highly susceptible to viral infections, however, the comprehensive features of COVID-19 in these patients remained largely unknown. The present study aimed to assess the clinical characteristics and outcomes of COVID-19 in a large cohort of cancer patients.Design, Setting, and ParticipantsData of consecutive cancer patients admitted to 33 designated hospitals for COVID-19 in Hubei province, China from December 17, 2019 to March 18, 2020 were retrospectively collected. The follow-up cutoff date was April 02, 2020. The clinical course and survival status of the cancer patients with COVID-19 were measured, and the potential risk factors of severe events and death were assessed through univariable and multivariable analyses.ResultsA total of 283 laboratory confirmed COVID-19 patients (50% male; median age, 63.0 years [IQR, 55.0 to 70.0]) with more than 20 cancer types were included. The overall mortality rate was 18% (50/283), and the median hospitalization stay for the survivors was 26 days. Amongst all, 76 (27%) were former cancer patients with curative resections for over five years without recurrence. The current cancer patients exhibited worse outcomes versus former cancer patients (overall survival, HR=2.45, 95%CI 1.10 to 5.44, log-rank p=0.02; mortality rate, 21% vs 9%). Of the 207 current cancer patients, 95 (46%) have received recent anti-tumor treatment, and the highest mortality rate was observed in the patients receiving recent chemotherapy (33%), followed by surgery (26%), other anti-tumor treatments (19%), and no anti-tumor treatment (15%). In addition, a higher mortality rate was observed in patients with lymphohematopoietic malignancies (LHM) (53%, 9/17), and all seven LHM patients with recent chemotherapy died. Multivariable analysis indicated that LHM (p=0.001) was one of the independent factors associating with critical illness or death.ConclusionsThis is the first systematic study comprehensively depicting COVID-19 in a large cancer cohort. Patients with tumors, especially LHM, may have poorer prognosis of COVID-19. Additional cares are warranted and non-emergency anti-tumor treatment should be cautiously used for these patients under the pandemic. more...
- Published
- 2020
- Full Text
- View/download PDF
21. Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
- Author
-
Aimin Zang, Zhe Liu, Lejie Cao, Kai Wang, Jun Chen, Liyan Jiang, Dianming Li, Yan Zhang, Shun Lu, Peiguo Cao, Yan Yang, Junquan Yang, Rong Wu, Chengshui Chen, Jiuwei Cui, Qitao Yu, Donglin Wang, Yiping Zhang, Xiangming Jin, Zhuang Yu, Guanming Jiang, Qingshan Li, Xiuyi Zhi, Guoping Sun, Tienan Yi, Qun Chen, Hong Jian, Min Zhao, H. Zhao, Liang’an Chen, R. Guo, Jianying Zhou, Yong Song, Yunchao Huang, Jian Zhang, Yueyin Pan, Xiaoling Li, Yunpeng Liu, Bin Wang, Shucai Zhang, Gang Wu, Ying Cheng, Jian Fang, Guojun Zhang, Dongqing Lv, Wu Zhuang, Cuimin Ding, Panwen Tian, Shundong Cang, and Gongyan Chen more...
- Subjects
Cancer Research ,medicine.medical_specialty ,Leukopenia ,business.industry ,Interstitial lung disease ,Phases of clinical research ,Cancer ,medicine.disease ,Gastroenterology ,Rash ,respiratory tract diseases ,T790M ,Oncology ,Internal medicine ,medicine ,Clinical endpoint ,medicine.symptom ,Lung cancer ,business - Abstract
D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156) Background: Despite initial response to EGFR-TKI, most patients (pts) develop resistance with the EGFR T790M mutation detectable in ~50% of patients treated with first-/second-generation EGFR-TKIs. D-0316 is a third-generation EGFR-TKI that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in pts with non-small cell lung cancer (NSCLC). We report the results of a registered, single-arm, phase II study of D-0316 in NSCLC pts with EGFR T790M who progressed on previous treatment with first-line EGFR-TKIs. Methods: In this phase II, open-label, single-arm study, eligible pts were those who had confirmed locally advanced or metastatic NSCLC, and had disease progression after first-line EGFR-TKI and with T790M mutation. Pts were initially orally given D-0316 50 mg. However, considering the benefits and risks of the pts, the dose was modified to 100 mg once daily with a 21-day lead-in at 75 mg once daily. The primary endpoint was objective response rate (ORR) based on independent review committee (IRC) according to RECIST 1.1.Results: As of October 31, 2019, 176 pts were enrolled in the 50 mg phase, in which 90 pts had partial response, achieving an ORR of 51.1% (95%CI: 43.5-58.7). Despite the immature PFS, disease progression or death occurred in 60 pts (34.1%) and the median PFS was 8.4 months (95% CI: 8.0-NE). Between September 12, 2019 and July 29, 2020, 689 pts were screened and 290 pts (median age 62.5) were enrolled in China and received 100mg D-0316 with a 21-day lead-in at 75 mg. At data cutoff (October 18, 2020), the median duration of follow-up was 5.5 months. 188 of the 290 pts achieved confirmed partial responses by IRC. The ORR was 64.8% (95% CI: 59.0-70.3) and the disease control rate (DCR) was 95.2% (95% CI: 92.0-97.3). The ORR was consistent across in most subgroups. Among 34 pts with brain metastases at baseline, 18 pts achieved confirmed partial responses and the intracranial ORR was 52.9% (95% CI: 35.1-70.2). The PFS, DoR, and OS were premature. The most common treatment-related adverse events were thrombocytopenia (57.2%), headache (27.6%), leukopenia (23.4%), anemia (22.1%) and rash (20.7%). The most common grade 3 or higher treatment-related adverse events were thrombocytopenia (11.7%). One death was due to treatment-related adverse events (interstitial lung disease). Six interstitial lung diseases (2.1%) were observed during study treatment. Conclusion: D-0316 has showed strong anti-tumor activities and tolerable toxicity in pts with EGFR T790M-positive NSCLC who have progressed after EGFR-TKI treatment. Citation Format: Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Xiangming Jin, Hong Jian, Chengshui Chen, Guanming Jiang, Panwen Tian, Kai Wang, Hui Zhao, Gongyan Chen, Qun Chen, Cuimin Ding, Junquan Yang, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Wu Zhuang, Zhe Liu, Jian Fang, Yunpeng Liu, Jian Zhang, Jun Chen, Yueyin Pan, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang. D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT170. more...
- Published
- 2021
- Full Text
- View/download PDF
22. Retracted: Long non‐coding RNA TP73‐AS1 facilitates progression and radioresistance in lung cancer cells by the miR‐216a‐5p/CUL4B axis with exosome involvement
- Author
-
Huibing Qiu, Lingyun Zhang, Yan Gong, Conghua Xie, Kai Yang, and Tienan Yi
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,business.industry ,Cancer ,Cell migration ,General Medicine ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:RC254-282 ,Exosome ,This Article Has Been Retracted and Is Available Online Only ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Tumor progression ,030220 oncology & carcinogenesis ,Radioresistance ,medicine ,Cancer research ,Tumor Protein p73 ,Radiosensitivity ,Lung cancer ,business - Abstract
Background Exosomes have significant implications in cancer progression via transferring various modulatory molecules. Long non-coding RNAs (lncRNAs) play essential biological roles in lung cancer. In this report, we unlock the functional mechanism of tumor protein P73 antisense RNA 1 (TP73-AS1) in lung cancer. Methods The expression analyses of TP73-AS1, microRNA-216a-5p (miR-216a-5p) and Cullin 4B (CUL4B) were performed by quantitative real-time polymerase chain reaction (qRT-PCR). Cell migration and invasion were assessed using wound healing and transwell assays. Flow cytometry was applied to determine cell apoptosis. Colony formation assay was performed for cell survival to evaluate the effect on radiosensitivity. The intergenic interaction was analyzed by dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. Western blot was used for associated protein determination. An in vivo experiment was conducted by establishing xenograft models in mice. Results TP73-AS1 was conspicuously overexpressed in lung cancer tissues and cells. Silencing TP73-AS1 restrained cell migration and invasion while it enhanced apoptosis and radiosensitivity of lung cancer. TP73-AS1 could bind to miR-216a-5p as well as miR-216a-5p and CUL4B. The function of TP73-AS1 downregulation in lung cancer was achieved by miR-216a-5p/CUL4B axis. Inhibition of TP73-AS1 also exerted an inhibitory effect on tumor growth and radioresistance in vivo potentially via regulating miR-216a-5p/CUL4B axis. Moreover, exosomes from lung cancer cells downregulated TP73-AS1 could repress tumor evolution and radioresistance. Conclusions Collectively, TP73-AS1 acted as a sponge of miR-216a-5p to regulate CUL4B in order to promote tumor progression and radioresistance in lung cancer cells with the implication of exosomes, which presents a novel mechanism of tumor action and radioresistance in lung cancer. Key points SIGNIFICANT FINDINGS OF THE STUDY: TP73-AS1 silence inhibits migration and invasion while elevates apoptosis and radiosensitivity in lung cancer cells TP73-AS1 targets miR-216a-5p and miR-216a-5p targets CUL4B WHAT THIS STUDY ADDS: Downregulation of TP73-AS1 reduces tumor growth and radioresistance in vivo via the miR-216a-5p/CUL4B axis Exosomes from si-TP73-AS1-transfected cells inhibits lung cancer progression and radioresistance. more...
- Published
- 2020
23. Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
- Author
-
Tao Jiang, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Yueyin Pan, Qin Shi, Guojun Zhang, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, and Aimin Zang more...
- Published
- 2021
- Full Text
- View/download PDF
24. Combined perioperative EOX chemotherapy and postoperative chemoradiotherapy for locally advanced gastric cancer
- Author
-
Zhimin Gong, Tienan Yi, Jia Yuan, Juan Zhao, and Qiushan He
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Perioperative ,Articles ,030204 cardiovascular system & hematology ,Surgery ,Oxaliplatin ,Capecitabine ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,business ,Survival rate ,Chemoradiotherapy ,medicine.drug ,Epirubicin - Abstract
Currently, adjunctive therapy for gastric cancer is not standardized worldwide and the most effective combination of different modalities has not been clearly determined. The aim of the present study was to retrospectively analyze the efficacy and toxicity of the combination of perioperative epirubicin, capecitabine and oxaliplatin (EOX) chemotherapy and postoperative concurrent chemoradiotherapy in the treatment of locally advanced gastric cancer. A total of 41 patients with locally advanced gastric cancer who had undergone perioperative EOX chemotherapy and surgical resection followed by chemoradiotherapy, were assessed. The perioperative EOX regimen consisted of 50 mg/m2 epirubicin and 130 mg/m2 oxaliplatin on day 1, with 625 mg/m2 capecitabine administered twice daily on days 1-21. The perioperative regimen was repeated 2-3 times every 3 weeks. After complete resection following the perioperative EOX regimen, concurrent chemoradiotherapy with capecitabine (4,500 cGy in daily fractions of 180 cGy administered 5 days per week for 5 weeks, with 625 mg/m2 capecitabine twice daily during radiotherapy) and 2 cycles of the EOX regimen 4 weeks after radiotherapy, were performed. In total, 30/41 patients (73.2%) completed all the planned treatments, including perioperative chemotherapy, surgical resection and chemoradiotherapy. The effective rate of preoperative chemotherapy (partial and complete response) was 56.1%; 30/41 patients received R0 resection, and the overall 3-year survival rate was 57.7%. Grade 3/4 gastrointestinal toxicity (nausea/vomiting) occurred in 22% of the patients, while 18 patients (43.9%) developed grade 3/4 hematological toxicity (granulocytopenia). The results of the present study indicated that the combination of perioperative EOX chemotherapy and postoperative concurrent chemoradiotherapy is feasible and effective for locally advanced gastric cancer. more...
- Published
- 2016
25. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer
- Author
-
Zhi-chun Song, Zhiming Hu, Zhen Zhang, Yue Lu, Dan Liu, Tienan Yi, Jimin Gao, Jinlong Li, Xiaoren Zhang, Zhen Wang, Qiushan He, Weihua Yin, Jia Tang, and Demin Wu
- Subjects
Male ,Cancer Research ,Paclitaxel ,T-Lymphocytes ,medicine.medical_treatment ,Immunology ,CD8-Positive T-Lymphocytes ,Cancer Vaccines ,Mice ,chemistry.chemical_compound ,Prostate cancer ,Lymphocytes, Tumor-Infiltrating ,Immune system ,Antigen ,Antigens, Neoplasm ,In vivo ,Cell Line, Tumor ,Tumor Cells, Cultured ,Animals ,Immunology and Allergy ,Medicine ,Chemotherapy ,business.industry ,Granulocyte-Macrophage Colony-Stimulating Factor ,Prostatic Neoplasms ,Cancer ,Dendritic Cells ,Immunotherapy ,Flow Cytometry ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Combined Modality Therapy ,Mice, Inbred C57BL ,Disease Models, Animal ,Oncology ,chemistry ,Cancer research ,business - Abstract
Chemotherapy combined with a tumor vaccine is an attractive approach in cancer therapy. This study was designed to investigate the optimal schedule and mechanisms of action of a novel GM-CSF (granulocyte-macrophage colony-stimulating factor) surface-modified tumor-cell vaccine in combination with paclitaxel in the treatment of mouse RM-1 prostate cancer. First, the anti-tumor efficiencies of various dosage of paclitaxel (4, 20, 40 mg/kg) in combination with the vaccine in different administration sequences were examined in the mouse RM-1 prostate cancer model. Then, the in vivo and in vitro effects of various dosage of paclitaxel on RM-1 cells, T cells, and DCs (dendritic cells) were evaluated. The results showed that: (a) the GM-CSF-surface-modified tumor-cell vaccine was more potent at inducing the uptake of tumor antigens by DCs than irradiated tumor cells plus free GM-CSF; (b) 4 mg/kg paclitaxel combined with the GM-CSF-surface-modified tumor-cell vaccine was the most effective at enhancing tumor regression in RM-1 prostate cancer mice when the vaccine was administrated 2 days after paclitaxel; and (c) administration of 4 mg/kg paclitaxel followed by the vaccine induced the highest degree of CD8(+) T-cell infiltration in tumor tissue, suggesting that the induction of tumor-specific immune response had occurred. These findings suggested that the GM-CSF-surface-modified tumor-cell vaccine may have potential clinical benefit for patients with prostate cancer when it is combined with paclitaxel. Furthermore, the effect of immunochemotherapy depends on careful selection of paclitaxel dosage and the sequence of paclitaxel/vaccine administration. more...
- Published
- 2011
- Full Text
- View/download PDF
26. Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201)
- Author
-
Haijun Zhong, Jianwei Yang, Mei Wang, Tienan Yi, Feng Ye, Zhong Xie, Lu Wen, Yuxian Bai, Jin Li, Tongfu Jia, Shukui Qin, Yi Ba, Xiaoyan Lin, Xiang-Yuan Wu, Yifu He, Yong Huang, Likun Liu, Guifang Zhang, Wenying Deng, and Junsheng Wang more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Prognostic factor ,business.industry ,Subgroup analysis ,Metastatic gastric cancer ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Apatinib ,In patient ,business - Abstract
e16028Background: Some studies have shown that number of metastatic sites is a significant prognostic factor in metastatic gastric cancer. In this subgroup analysis, data from a large phase IV tria... more...
- Published
- 2018
- Full Text
- View/download PDF
27. Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study
- Author
-
Zhong Xie, Mei Wang, Lu Wen, Wenying Deng, Xiaoyan Lin, Jin Li, Yong Huang, Xiang-Yuan Wu, Jianwei Yang, Yifu He, Shukui Qin, Feng Ye, Tienan Yi, Tongfu Jia, Likun Liu, Junsheng Wang, Guifang Zhang, Yuxian Bai, Haijun Zhong, and Yi Ba more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,030204 cardiovascular system & hematology ,Routine practice ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Apatinib ,Adverse effect ,business - Abstract
4039Background: Ahead-G201, a multicenter Phase IV study, is conducting to evaluate apatinib as third-line or beyond therapy in a routine practice setting of gastric cancer patients (pts). Methods:... more...
- Published
- 2018
- Full Text
- View/download PDF
28. BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201)
- Author
-
Likun Liu, Yuxian Bai, Zhong Xie, Mei Wang, Junsheng Wang, Wenying Deng, Yifu He, Tongfu Jia, Shukui Qin, Guifang Zhang, Feng Ye, Xiaoyan Lin, Lu Wen, Xiang-Yuan Wu, Tienan Yi, Jin Li, Haijun Zhong, Yong Huang, Yi Ba, and Jianwei Yang more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Large population ,nutritional and metabolic diseases ,Advanced gastric cancer ,Affect (psychology) ,Metastatic gastric cancer ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Apatinib ,In patient ,business - Abstract
e16027Background: Studies have shown BMI could affect long-term survival in advanced gastric cancer. In this analysis, based on a large population, we further investigated the effects of BMI on the... more...
- Published
- 2018
- Full Text
- View/download PDF
29. Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer
- Author
-
Tongfu Jia, Feng Ye, Xiaoyan Lin, Mei Wang, Zhong Xie, Yuxian Bai, Yifu He, Haijun Zhong, Guifang Zhang, Xiang-Yuan Wu, Wenying Deng, Likun Liu, Junsheng Wang, Lu Wen, Shukui Qin, Yi Ba, Yong Huang, Tienan Yi, Jianwei Yang, and Jin Li more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,digestive, oral, and skin physiology ,medicine.disease ,digestive system diseases ,Metastatic gastric cancer ,stomatognathic diseases ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Adenocarcinoma ,Apatinib ,business - Abstract
e16020Background: Apatinib has been approved in China for patients (pts) with advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma after at least two lines of systemic chemo... more...
- Published
- 2018
- Full Text
- View/download PDF
30. Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study
- Author
-
Shukui Qin, Haijun Zhong, Zhong Xie, Yi Ba, Xiang-Yuan Wu, Jianwei Yang, Tienan Yi, Xiaoyan Lin, Jin Li, Lu Wen, Guifang Zhang, Mei Wang, Wenying Deng, Junsheng Wang, Yifu He, Tongfu Jia, Yong Huang, Feng Ye, Yuxian Bai, and Likun Liu more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Advanced gastric cancer ,respiratory tract diseases ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Medicine ,Apatinib ,Vegfr tki ,business ,neoplasms - Abstract
e16026Background: Apatinib, a small molecule VEGFR TKI, has been approved in the treatment of advanced gastric cancer in China. The real benefits of apatinib for different patients (pts) with ECOG ... more...
- Published
- 2018
- Full Text
- View/download PDF
31. Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201)
- Author
-
Zhong Xie, Likun Liu, Yuxian Bai, Mei Wang, Tongfu Jia, Haijun Zhong, Lu Wen, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Guifang Zhang, Junsheng Wang, Jin Li, Yi Ba, Xiang-Yuan Wu, Yifu He, Yong Huang, Feng Ye, Wenying Deng, and Tienan Yi more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,030204 cardiovascular system & hematology ,medicine.disease ,Metastatic gastric cancer ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Third line ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Apatinib ,business - Abstract
e16019Background: An open-label, multicenter, post-marketing Phase IV study of apatinib (Ahead-G201; ClinicalTrials.gov: NCT02426034) is being conducted in a broad range of gastric cancer patients ... more...
- Published
- 2018
- Full Text
- View/download PDF
32. Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201)
- Author
-
Haijun Zhong, Mei Wang, Yuxian Bai, Lu Wen, Junsheng Wang, Xiang-Yuan Wu, Xiaoyan Lin, Zhong Xie, Likun Liu, Yi Ba, Shukui Qin, Yifu He, Guifang Zhang, Yong Huang, Wenying Deng, Tongfu Jia, Feng Ye, Jin Li, Tienan Yi, and Jianwei Yang more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Time to progression ,business.industry ,Advanced gastric cancer ,Tyrosine-kinase inhibitor ,chemistry.chemical_compound ,First line therapy ,Tolerability ,chemistry ,Internal medicine ,medicine ,Apatinib ,business - Abstract
e16021Background: Apatinib is a small molecule tyrosine kinase inhibitor that targets VEGFR-2. Due to good safety, tolerability and efficacy, apatinib has been approved in the treatment of pretreat... more...
- Published
- 2018
- Full Text
- View/download PDF
33. Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study
- Author
-
Jianwei Yang, Jin Li, Yi Ba, Tongfu Jia, Zhong Xie, Mei Wang, Xiang-Yuan Wu, Yuxian Bai, Feng Ye, Guifang Zhang, Yong Huang, Haijun Zhong, Wenying Deng, Likun Liu, Lu Wen, Xiaoyan Lin, Shukui Qin, Tienan Yi, Junsheng Wang, and Yifu He more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Subgroup analysis ,Gastric carcinoma ,Advanced gastric cancer ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Medicine ,Apatinib ,In patient ,cardiovascular diseases ,business ,Adverse effect - Abstract
e16022Background: Hypertension (HTN) is one of the most common adverse events (AEs) associated with apatinib treatment in gastric carcinoma. However, few studies focus on the effect of HTN history ... more...
- Published
- 2018
- Full Text
- View/download PDF
34. [Combined chemotherapy with domestic gemcitabine plus carboplatin in the treatment of advanced non-small cell lung cancer]
- Author
-
Qiushan, He, Tienan, Yi, Lingyun, Zhang, and Zhihua, Sun
- Abstract
Chemotherapy is very important in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy, clinical benefit and toxicity of combined chemotherapy with domestic gemcitabine (ZEFEI) plus carboplatin in the treatment of advanced NSCLC.Thirty-four previously untreated patients with advanced NSCLC (stage III-IV) received domestic gemcitabine of 1000mg/m² on days 1, 8, and carboplatin of AUC 5 on day 1, with 21 days as a cycle. Each patient received at least three cycles.The total clinical response rate (complete and partial response) was 44% (15/34). Overall clinical benefit rate was 53% (18/34). The main toxicities were hematological toxicities. The rate of grade III-IV leukopenia and thrombocytopenia was 47% and 24% respectively.Combined chemotherapy with domestic gemcitabine plus carboplatin is an effective and feasible regimen for advanced NSCLC. more...
- Published
- 2010
35. [A randomized trial of NVB plus DDP with versus without thalidomide in the treatment of advanced non small cell lung cancer.]
- Author
-
Qiushan, He, Tienan, Yi, Bin, Luo, and Xiaolin, Zhang
- Published
- 2010
36. Combined perioperative EOX chemotherapy and postoperative chemoradiotherapy for locally advanced gastric cancer.
- Author
-
QIUSHAN HE, JUAN ZHAO, JIA YUAN, ZHIMIN GONG, and TIENAN YI
- Subjects
STOMACH cancer ,CANCER chemotherapy ,CHEMORADIOTHERAPY ,ANTINEOPLASTIC agents ,PERIOPERATIVE care - Abstract
Currently, adjunctive therapy for gastric cancer is not standardized worldwide and the most effective combination of different modalities has not been clearly determined. The aim of the present study was to retrospectively analyze the efficacy and toxicity of the combination of perioperative epirubicin, capecitabine and oxaliplatin (EOX) chemotherapy and postoperative concurrent chemoradiotherapy in the treatment of locally advanced gastric cancer. A total of 41 patients with locally advanced gastric cancer who had undergone perioperative EOX chemotherapy and surgical resection followed by chemoradiotherapy, were assessed. The perioperative EOX regimen consisted of 50 mg/m2 epirubicin and 130 mg/m2 oxaliplatin on day 1, with 625 mg/m2 capecitabine administered twice daily on days 1-21. The perioperative regimen was repeated 2-3 times every 3 weeks. After complete resection following the perioperative EOX regimen, concurrent chemoradiotherapy with capecitabine (4,500 cGy in daily fractions of 180 cGy administered 5 days per week for 5 weeks, with 625 mg/m2 capecitabine twice daily during radiotherapy) and 2 cycles of the EOX regimen 4 weeks after radiotherapy, were performed. In total, 30/41 patients (73.2%) completed all the planned treatments, including perioperative chemotherapy, surgical resection and chemoradiotherapy. The effective rate of preoperative chemotherapy (partial and complete response) was 56.1%; 30/41 patients received R0 resection, and the overall 3-year survival rate was 57.7%. Grade 3/4 gastrointestinal toxicity (nausea/vomiting) occurred in 22% of the patients, while 18 patients (43.9%) developed grade 3/4 hematological toxicity (granulocytopenia). The results of the present study indicated that the combination of perioperative EOX chemotherapy and postoperative concurrent chemoradiotherapy is feasible and effective for locally advanced gastric cancer. [ABSTRACT FROM AUTHOR] more...
- Published
- 2017
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.